¼¼°èÀÇ Á¤Çü¿Ü°ú¿ë Àç»ý ¼ö¼ú¿ë Á¦Ç° ½ÃÀå
Orthopedic Regenerative Surgical Products
»óǰÄÚµå : 1775044
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 07¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 384 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,239,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,719,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

¼¼°è Á¤Çü¿Ü°ú¿ë Àç»ý ¼ö¼ú¿ë Á¦Ç° ½ÃÀåÀº 2030³â±îÁö 49¾ï ´Þ·¯¿¡ µµ´Þ

2024³â¿¡ 43¾ï ´Þ·¯·Î ÃßÁ¤µÇ´Â Á¤Çü¿Ü°ú¿ë Àç»ý ¼ö¼ú¿ë Á¦Ç° ¼¼°è ½ÃÀåÀº 2024-2030³â°£ CAGR 2.2%·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â 49¾ï ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. º» º¸°í¼­¿¡¼­ ºÐ¼®ÇÑ ºÎ¹® Áß ÇϳªÀÎ ºñ½ºÄÚ ¼­Çø®¸ÕÆ®´Â CAGR 1.9%¸¦ ³ªÅ¸³»°í, ºÐ¼® ±â°£ Á¾·á½Ã¿¡´Â 22¾ï ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. µ¿Á¾ÀÌ½ÄÆí ºÎ¹®ÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£Áß CAGR 1.6%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 12¾ï ´Þ·¯·Î ÃßÁ¤, Áß±¹Àº CAGR 4.2%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ Á¤Çü¿Ü°ú¿ë Àç»ý ¼ö¼ú¿ë Á¦Ç° ½ÃÀåÀº 2024³â¿¡ 12¾ï ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ °æÁ¦´ë±¹ÀÎ Áß±¹Àº ºÐ¼® ±â°£ÀÎ 2024-2030³â°£ CAGR 4.2%·Î 2030³â±îÁö 9¾ï 3,390¸¸ ´Þ·¯ ±Ô¸ð¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ±âŸ ÁÖ¸ñÇØ¾ß ÇÒ Áö¿ªº° ½ÃÀåÀ¸·Î¼­´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖÀ¸¸ç, ºÐ¼® ±â°£Áß CAGRÀº °¢°¢ 0.8%¿Í 1.6%¸¦ º¸ÀÏ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR 1.1%·Î ¼ºÀåÇÒ Àü¸ÁÀÔ´Ï´Ù.

¼¼°èÀÇ Á¤Çü¿Ü°ú¿ë Àç»ý ¼ö¼ú¿ë Á¦Ç° ½ÃÀå - ÁÖ¿ä µ¿Çâ°ú ÃËÁø¿äÀÎ Á¤¸®

Àç»ý ¼Ö·ç¼ÇÀÌ Á¤Çü¿Ü°úÀÇ ¹Ì·¡¸¦ À籸¼ºÇÒ ¼ö ÀÖÀ»±î?

»À, ¿¬°ñ, ¿¬ºÎÁ¶Á÷ÀÇ ¼öº¹¿¡ Çõ½ÅÀûÀÎ ¼Ö·ç¼ÇÀ» Á¦°øÇÏ´Â Àç»ýÀÇ·á ºÐ¾ßÀÇ ¹ßÀü¿¡ µû¶ó Á¤Çü¿Ü°ú¿ë Àç»ý¿Ü°ú Á¦Ç°¿¡ ´ëÇÑ ¼ö¿ä°¡ ±ÞÁõÇϰí ÀÖ½À´Ï´Ù. ±âÁ¸ÀÇ ÀÓÇöõÆ®³ª Àΰø°üÀý°ú ´Þ¸®, Àç»ýÀÇ·á Á¦Ç°Àº »ýü Ȱ¼º ¹°Áú, Áٱ⼼Æ÷, Á¶Á÷°øÇÐÀ» Ȱ¿ëÇÏ¿© ÀÚ¿¬ Ä¡À¯¿Í Á¶Á÷ Àç»ýÀ» ÃËÁøÇÕ´Ï´Ù. ÀÌ Á¢±Ù¹ýÀº °ñ°üÀý¿°, ½ºÆ÷Ã÷ Áúȯ, ÅðÇ༺ ±Ù°ñ°Ý°è ÁúȯÀ» ¾Î°í Àִ ȯÀڵ鿡°Ô ƯÈ÷ À¯¿ëÇÕ´Ï´Ù. ÀÚ°¡ ¹× µ¿Á¾ ¼¼Æ÷ ¿ä¹ý, ¼ºÀå ÀÎÀÚ, ½ºÄ³Æú´õÀÇ »ç¿ëÀÌ Áõ°¡ÇÔ¿¡ µû¶ó ȸº¹ ½Ã°£À» ´ÜÃàÇϰí Àå±âÀûÀÎ ¼ö¼ú °á°ú¸¦ °³¼±ÇÔÀ¸·Î½á Á¤Çü¿Ü°ú ¼ö¼úÀÇ »óȲÀÌ ¿ÏÀüÈ÷ ¹Ù²î°í ÀÖ½À´Ï´Ù.

½ÃÀåÀ» ÁÖµµÇÏ´Â ÃÖ÷´Ü ±â¼úÀ̶õ?

Á¤Çü¿Ü°ú¿ë Àç»ý¼ö¼ú Á¦Ç° ½ÃÀåÀº »ýüÀç·á, 3D ¹ÙÀÌ¿ÀÇÁ¸°ÆÃ, À¯ÀüÀÚ Ä¡·á ºÐ¾ß¿¡¼­ ȹ±âÀûÀÎ ¹ßÀüÀ» °ÅµìÇϰí ÀÖ½À´Ï´Ù. õ¿¬ Á¶Á÷ ±¸Á¶¸¦ ¸ð¹æÇÑ »ýü°øÇÐ ½ºÄ³ÆúµåÀÇ °³¹ß·Î ¼¼Æ÷ Áõ½Ä°ú ¼÷ÁÖ Á¶Á÷°úÀÇ ÅëÇÕÀÌ ÃËÁøµÇ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ´ÙÇ÷¼ÒÆÇ Ç÷Àå(PRP)°ú Áß°£¿± Áٱ⼼Æ÷(MSC)¸¦ ±â¹ÝÀ¸·Î ÇÑ Ä¡·á¹ýÀÇ ÃâÇöÀº ¿¬°ñ ¹× ÈûÁÙ ¼Õ»ó¿¡ ´ëÇÑ ¼ö¼ú ¿ÜÀÇ ´ë¾ÈÀ» Á¦°øÇÕ´Ï´Ù. ¿¬±¸ÀÚµéÀº ¶ÇÇÑ CRISPR°ú °°Àº À¯ÀüÀÚ ÆíÁý ±â¼úÀ» ޱ¸ÇÏ¿© ºÐÀÚ ¼öÁØ¿¡¼­ Á¶Á÷ Àç»ýÀ» °­È­ÇÏ´Â ¹æ¹ýÀ» ¸ð»öÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ±â¼úÀÇ ¹ßÀüÀ¸·Î Àç»ý Ä¡·á´Â ´õ¿í È¿°úÀûÀ̰í Á¢±ÙÇϱ⠽¬¿öÁö°í ÀÖ½À´Ï´Ù.

Á¤Çü¿Ü°ú¿ë Àç»ý Á¦Ç°ÀÇ º¸±Þ¿¡ ¾î¶² À庮ÀÌ Àִ°¡?

Àç»ý ¼Ö·ç¼ÇÀÇ ÀáÀç·Â¿¡µµ ºÒ±¸ÇÏ°í ±ÔÁ¦ ´ç±¹ÀÇ ½ÂÀÎ, ³ôÀº ºñ¿ë, ȯÀÚ ¹ÝÀÀÀÇ ÆíÂ÷ µîÀÇ °úÁ¦°¡ ³²¾ÆÀÖ½À´Ï´Ù. »ý¹°ÇÐÀû Ȱ¼º ¹°ÁúÀÇ °³¹ß ¹× Ç¥ÁØÈ­ÀÇ º¹À⼺Àº ±ÔÁ¦ À庮À¸·Î ÀÛ¿ëÇÏ¿© »õ·Î¿î Ä¡·á¹ýÀÇ »ó¿ëÈ­¸¦ Áö¿¬½Ã۰í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, Àç»ýÄ¡·á¿¡ ´ëÇÑ º¸Çè±Þ¿©ÀÇ ¾î·Á¿òÀº ȯÀÚµéÀÇ Á¢±Ù¼ºÀ» Á¦ÇÑÇϰí ÀÖ½À´Ï´Ù. ±×·¯³ª ÀÓ»ó½ÃÇè Áõ°¡, ±ÔÁ¦ ¹ßÀü ¹× ¾÷°è¿ÍÀÇ Çù·ÂÀ¸·Î ÀÌ·¯ÇÑ À庮À» ±Øº¹ÇÏ°í º¸´Ù ±¤¹üÀ§ÇÑ Ã¤ÅÃÀ» À§ÇÑ ±æÀÌ ¿­¸®°í ÀÖ½À´Ï´Ù.

Á¤Çü¿Ü°ú¿ë Àç»ý ¼ö¼ú Á¦Ç° ½ÃÀåÀÇ ¼ºÀåÀ» À̲ô´Â ¿äÀÎÀº ¹«¾ùÀΰ¡?

Á¤Çü¿Ü°ú¿ë Àç»ý ¼ö¼ú Á¦Ç° ½ÃÀåÀÇ ¼ºÀåÀº ÃÖ¼Ò Ä§½ÀÀûÀÌ°í »ý¹°ÇÐÀûÀ¸·Î ÅëÇÕµÈ Ä¡·á¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡, Á¶Á÷ °øÇÐÀÇ ¹ßÀü, Áٱ⼼Æ÷ ¿¬±¸¿¡ ´ëÇÑ ÅõÀÚ Áõ°¡ µî ¿©·¯ ¿äÀο¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù. °ñ°üÀý¿°°ú ½ºÆ÷Ã÷ ºÎ»óÀÇ À¯º´·ü Áõ°¡´Â Àç»ý ¼Ö·ç¼ÇÀÇ Çʿ伺À» °¡¼ÓÈ­Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ¹ÙÀÌ¿ÀÇÁ¸°ÆÃ ¹× »ýüÀç·áÀÇ ±â¼ú Çõ½ÅÀÌ È®´ëµÇ¸é¼­ Â÷¼¼´ë Àç»ý ÀÓÇöõÆ® °³¹ßÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ±ÔÁ¦ °æ·ÎÀÇ °³¼±°ú Á¤Çü¿Ü°ú Áø·á¿¡¼­ Àç»ý Ä¡·áÀÇ ¼ö¿ëÀÌ È®´ëµÇ¸é¼­ ½ÃÀå È®´ë¿¡ ´õ¿í ¹ÚÂ÷¸¦ °¡Çϰí ÀÖ½À´Ï´Ù.

ºÎ¹®

Á¦Ç°(Á¡¾× º¸ÃæÁ¦, µ¿Á¾ÀÌ½ÄÆí, ÇÕ¼º ¼ö¼ú¿ë Á¦Ç°, ¼¼Æ÷ ±â¹Ý ¼ö¼ú¿ë Á¦Ç°), ¿ëµµ(°üÀý Àç°Ç ¿ëµµ, Á¤Çü¿Ü°ú ÅëÁõ °ü¸® ¿ëµµ, ¿Ü»ó ¼öº¹ ¿ëµµ, ¿¬°ñ¡¤°Ç¼öº¹ ¿ëµµ, ±âŸ ¿ëµµ), ÃÖÁ¾ ¿ëµµ(º´¿ø ÃÖÁ¾ ¿ëµµ, ¿Ü·¡¼ö¼ú¼¾ÅÍ(ASC) ÃÖÁ¾ ¿ëµµ, ±âŸ ÃÖÁ¾ ¿ëµµ)

Á¶»ç ´ë»ó ±â¾÷ ¿¹

AI ÅëÇÕ

Global Industry Analysts´Â À¯È¿ÇÑ Àü¹®°¡ ÄÁÅÙÃ÷¿Í AIÅø¿¡ ÀÇÇØ ½ÃÀå Á¤º¸¿Í °æÀï Á¤º¸¸¦ º¯ÇõÇϰí ÀÖ½À´Ï´Ù.

Global Industry Analysts´Â ÀϹÝÀûÀÎ LLM³ª ¾÷°èº° SLM Äõ¸®¿¡ µû¸£´Â ´ë½Å¿¡, ºñµð¿À ±â·Ï, ºí·Î±×, °Ë»ö ¿£Áø Á¶»ç, ´ë·® ±â¾÷, Á¦Ç°/¼­ºñ½º, ½ÃÀå µ¥ÀÌÅÍ µî, Àü ¼¼°è Àü¹®°¡·ÎºÎÅÍ ¼öÁýÇÑ ÄÁÅÙÃ÷ ¸®Æ÷ÁöÅ丮¸¦ ±¸ÃàÇß½À´Ï´Ù.

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»çÀÇ ±¹°¡, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±â¹ÝÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇß½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ¼öÀÍ¿ø°¡(COGS) Áõ°¡, ¼öÀͼº °¨¼Ò, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû ¹× °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

LSH
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Orthopedic Regenerative Surgical Products Market to Reach US$4.9 Billion by 2030

The global market for Orthopedic Regenerative Surgical Products estimated at US$4.3 Billion in the year 2024, is expected to reach US$4.9 Billion by 2030, growing at a CAGR of 2.2% over the analysis period 2024-2030. Viscosupplements, one of the segments analyzed in the report, is expected to record a 1.9% CAGR and reach US$2.2 Billion by the end of the analysis period. Growth in the Allografts segment is estimated at 1.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.2 Billion While China is Forecast to Grow at 4.2% CAGR

The Orthopedic Regenerative Surgical Products market in the U.S. is estimated at US$1.2 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$933.9 Million by the year 2030 trailing a CAGR of 4.2% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 0.8% and 1.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.1% CAGR.

Global Orthopedic Regenerative Surgical Products Market - Key Trends & Drivers Summarized

Can Regenerative Solutions Reshape the Future of Orthopedic Surgery?

The demand for orthopedic regenerative surgical products is surging as the field of regenerative medicine advances, offering innovative solutions for bone, cartilage, and soft tissue repair. Unlike traditional implants or prosthetics, regenerative products leverage bioactive materials, stem cells, and tissue engineering to promote natural healing and tissue regeneration. This approach is particularly beneficial for patients suffering from osteoarthritis, sports injuries, and degenerative musculoskeletal disorders. The rising adoption of autologous and allogeneic cell therapies, growth factors, and scaffolds is transforming the orthopedic landscape by reducing recovery time and improving long-term surgical outcomes.

What Cutting-Edge Technologies Are Driving the Market Forward?

The orthopedic regenerative surgical products market is witnessing breakthroughs in biomaterials, 3D bioprinting, and gene therapy. The development of bioengineered scaffolds that mimic natural tissue structures is enhancing cell proliferation and integration with host tissues. Additionally, the emergence of platelet-rich plasma (PRP) and mesenchymal stem cell (MSC)-based therapies is providing non-surgical alternatives for cartilage repair and tendon injuries. Researchers are also exploring gene editing techniques such as CRISPR to enhance tissue regeneration at the molecular level. These technological advancements are making regenerative therapies more effective and accessible.

What Barriers Exist to the Widespread Adoption of Orthopedic Regenerative Products?

Despite the potential of regenerative solutions, challenges remain in terms of regulatory approval, high costs, and variability in patient response. The complexity of developing and standardizing biologically active materials poses regulatory hurdles, slowing the commercialization of new therapies. Additionally, reimbursement challenges for regenerative procedures limit accessibility for patients. However, increasing clinical trials, regulatory advancements, and industry collaborations are addressing these barriers, paving the way for broader adoption.

What’s Fueling the Growth of the Orthopedic Regenerative Surgical Products Market?

The growth in the orthopedic regenerative surgical products market is driven by several factors, including rising demand for minimally invasive and biologically integrative treatments, advancements in tissue engineering, and increasing investments in stem cell research. The growing prevalence of osteoarthritis and sports injuries is accelerating the need for regenerative solutions. Additionally, the expansion of bioprinting and biomaterial innovations is driving the development of next-generation regenerative implants. Improved regulatory pathways and increased acceptance of regenerative therapies in orthopedic practice are further fueling market expansion.

SCOPE OF STUDY:

The report analyzes the Orthopedic Regenerative Surgical Products market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product (Viscosupplements, Allografts, Synthetic Surgical Products, Cell-based Surgical Products); Application (Joint Reconstruction Application, Orthopedic Pain Management Application, Trauma Repair Application, Cartilage & Tendon Repair Application, Other Applications); End-Use (Hospitals End-Use, Ambulatory Surgery Centers End-Use, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 42 Featured) -

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â